Viewpoint: The Human Capital Approach to Inference

The purpose of this essay is to discuss two approaches to inference, and how "human capital" can provide a way to combine them. The first approach, ubiquitous in economics, is based upon the Rubin/Holland potential outcomes model and relies upon randomized treatment to measure the causal effect of choice. The second approach, widely used in the pattern recognition and machine learning literatures, assumes that choice conditional upon current information is optimal (or at least high quality), and then provides techniques to generalize observed choice to new cases. The "human capital" approach combines these methods by using observed decisions by experts to reduce the demensionality of the feature space and allow the categorization of decisions by their propensity score. The fact that the human capital of experts is heterogeneous implies that errors in decision making are inevitable. Moreover, under the appropriate conditions, these decisions are random conditional upon the propensity score. This in turn allows us to identify the conditional average treatment effect for a wider class of situations than would be possible with randomized control trials. This point is illustrated with data from medical decision making in the context of treating depression, heart disease, and adverse childbirth events.

[1]  P. Bech,et al.  Escitalopram dose-response revisited: an alternative psychometric approach to evaluate clinical effects of escitalopram compared to citalopram and placebo in patients with major depression. , 2004, The international journal of neuropsychopharmacology.

[2]  K. Popper,et al.  Conjectures and refutations;: The growth of scientific knowledge , 1972 .

[3]  U. Lepola,et al.  Escitalopram (10–20 mg/day) is effective and well tolerated in a placebo‐controlled study in depression in primary care , 2003, International clinical psychopharmacology.

[4]  R. Findling,et al.  A double-blind, randomized, placebo-controlled trial of escitalopram in the treatment of pediatric depression. , 2006, Journal of the American Academy of Child and Adolescent Psychiatry.

[5]  Rajeev Dehejia,et al.  Program Evaluation as a Decision Problem , 1999 .

[6]  P. Kuhn,et al.  Lab Labor: What Can Labor Economists Learn from the Lab? , 2010, SSRN Electronic Journal.

[7]  G. Imbens,et al.  Efficient Estimation of Average Treatment Effects Using the Estimated Propensity Score , 2000 .

[8]  K. Popper,et al.  Conjectures and refutations;: The growth of scientific knowledge , 1972 .

[9]  Huaiyu Yang,et al.  Rating Scales for Depression , 2009 .

[10]  J. Mendels,et al.  Sertraline safety and efficacy in major depression: A double-blind fixed-dose comparison with placebo , 1995, Biological Psychiatry.

[11]  D. Hamermesh Six Decades of Top Economics Publishing: Who and How? , 2012 .

[12]  Ching Y. Suen,et al.  Historical review of OCR research and development , 1992, Proc. IEEE.

[13]  S. Stahl Placebo-controlled comparison of the selective serotonin reuptake inhibitors citalopram and sertraline , 2000, Biological Psychiatry.

[14]  E. Armstrong,et al.  Escitalopram versus sertraline in the treatment of major depressive disorder: a randomized clinical trial* , 2007, Current medical research and opinion.

[15]  Joshua D. Angrist,et al.  Identification of Causal Effects Using Instrumental Variables , 1993 .

[16]  James J Heckman,et al.  Building Bridges between Structural and Program Evaluation Approaches to Evaluating Policy , 2010, Journal of economic literature.

[17]  M. Rehavi,et al.  Physicians Treating Physicians: Information and Incentives in Childbirth , 2013 .

[18]  M. Dickstein Physician vs. Patient Incentives in Prescription Drug Choice , 2014 .

[19]  Alexander C. McLain,et al.  Multiple Testing of Composite Null Hypotheses in Heteroscedastic Models , 2012 .

[20]  R. Findling,et al.  Escitalopram in the treatment of adolescent depression: a randomized, double-blind, placebo-controlled extension trial. , 2013, Journal of child and adolescent psychopharmacology.

[21]  F. Yates The analysis of replicated experiments when the field results are incomplete , 1933 .

[22]  G. Arbanas Diagnostic and Statistical Manual of Mental Disorders (DSM-5) , 2015 .

[23]  M. Rynn,et al.  Sertraline in children and adolescents with major depressive disorder. , 2006, Journal of the American Academy of Child and Adolescent Psychiatry.

[24]  Stuart R Lipsitz,et al.  Relationship Between Cesarean Delivery Rate and Maternal and Neonatal Mortality. , 2015, JAMA.

[25]  G. Emslie,et al.  Escitalopram in the treatment of adolescent depression: a randomized placebo-controlled multisite trial. , 2009, Journal of the American Academy of Child and Adolescent Psychiatry.

[26]  J. I The Design of Experiments , 1936, Nature.

[27]  G. Imbens,et al.  Machine Learning Methods for Estimating Heterogeneous Causal Eects , 2015 .

[28]  E. Vytlacil Independence, Monotonicity, and Latent Index Models: An Equivalence Result , 2002 .

[29]  M. Owings,et al.  Physician Financial Incentives and Cesarean Section Delivery , 1994, The Rand journal of economics.

[30]  E. Cook,et al.  Sertraline in children and adolescents with obsessive-compulsive disorder: a multicenter randomized controlled trial. , 1998, JAMA.

[31]  László Györfi,et al.  A Probabilistic Theory of Pattern Recognition , 1996, Stochastic Modelling and Applied Probability.

[32]  Jeffrey A. Smith,et al.  Does Matching Overcome Lalonde's Critique of Nonexperimental Estimators? , 2000 .

[33]  J. Skinner,et al.  DIAGNOSIS AND UNNECESSARY PROCEDURE USE: EVIDENCE FROM C-SECTION , 2013 .

[34]  P. Llorca,et al.  Efficacy of escitalopram in patients with severe depression: a pooled analysis , 2005, International journal of clinical practice.

[35]  Alan Manning,et al.  The Credibility Revolution in Empirical Economics: How Better Research Design is Taking the Con Out of Econometrics , 2010, SSRN Electronic Journal.

[36]  W. MacLeod,et al.  Provider practice style and patient health outcomes: The case of heart attacks. , 2016, Journal of health economics.

[37]  Joshua D. Angrist,et al.  The Credibility Revolution in Empirical Economics: How Better Research Design is Taking the Con Out of Econometrics , 2010, SSRN Electronic Journal.

[38]  C. Porter,et al.  Mysteries and Conspiracies: Detective Stories, Spy Novels and the Making of Modern Societies , 2014 .

[39]  Bo E. Honoré,et al.  The Empirical Content of the Roy Model , 1990 .

[40]  Imran Rasul,et al.  Field Experiments in Labor Economics , 2010 .

[41]  Lee Baer,et al.  Handbook of Clinical Rating Scales and Assessment in Psychiatry and Mental Health , 2010, Current Clinical Psychiatry.

[42]  D. Freedman Statistical Models for Causation , 2006, Evaluation review.

[43]  J. Angrist,et al.  Empirical Strategies in Labor Economics , 1998 .

[44]  U. Lepola,et al.  Escitalopram 10 mg/day is effective and well tolerated in a placebo-controlled study in depression in primary care , 2002, International clinical psychopharmacology.

[45]  Eric R. Ziegel,et al.  The Elements of Statistical Learning , 2003, Technometrics.

[46]  Julie Bynum,et al.  Regional variations in diagnostic practices. , 2010, The New England journal of medicine.

[47]  P. Cuijpers,et al.  Comparative efficacy and tolerability of antidepressants for major depressive disorder in children and adolescents: a network meta-analysis , 2016, The Lancet.

[48]  A. Roy Some thoughts on the distribution of earnings , 1951 .

[49]  P. Llorca,et al.  Traitement des épisodes dépressifs sévères : escitalopram est plus efficace que citalopram , 2004 .

[50]  P. Holland Statistics and Causal Inference , 1985 .

[51]  A. Epstein,et al.  The Formation and Evolution of Physician Treatment Styles: An Application to Cesarean Sections , 2005, Journal of health economics.

[52]  W. MacLeod,et al.  Physician Practice Style and Patient Health Outcomes: The Case of Heart Attacks , 2015 .

[53]  B. Shepherd,et al.  GUIDO IMBENS, DONALD RUBIN, Causal Inference for Statistics, Social, and Biomedical Sciences: An Introduction. New York: Cambridge University Press. , 2016, Biometrics.

[54]  John C. Ham,et al.  Special issue on Experimental and non-experimental evaluation of economic policy and models , 2005 .

[55]  Han Bleichrodt,et al.  Handbook of Health Economics , 2001 .

[56]  D. Rubin,et al.  The central role of the propensity score in observational studies for causal effects , 1983 .

[57]  Abhijit Banerjee,et al.  The Experimental Approach to Development Economics , 2008 .

[58]  Jiaying Gu,et al.  Oracle and Adaptive False Discovery Rate Controlling Methods for One�?Sided Testing: Theory and Application in Treatment Effect Evaluation , 2018 .

[59]  D. Kahneman,et al.  Conditions for intuitive expertise: a failure to disagree. , 2009, The American psychologist.

[60]  W. MacLeod,et al.  First Do No Harm?: Tort Reform and Birth Outcomes , 2006 .

[61]  M. Knapp,et al.  Economics and mental health , 1994 .

[62]  U. Lepola,et al.  Escitalopram 10 mg/day is effective and well tolerated in a placebo-controlled study in depression in primary care. , 2003 .

[63]  Heidi L. Williams,et al.  Sources of Geographic Variation in Health Care: Evidence from Patient Migration , 2014, The quarterly journal of economics.

[64]  Amitabh Chandra,et al.  Who Ordered That? The Economics of Treatment Choices in Medical Care , 2011 .

[65]  James J. Heckman,et al.  Assessing the Case for Social Experiments , 1995 .

[66]  Marvin C. Alkin,et al.  What Have We Learned? , 2019, Stumbling Blocks Against Unification.

[67]  Angus Deaton Instruments, Randomization, and Learning about Development , 2010 .

[68]  T. Mcguire,et al.  Chapter 16 Economics and mental health , 2000 .

[69]  P. Mahalanobis On large-scale sample surveys , 1944, Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences.

[70]  W. Burke,et al.  Fixed-dose trial of the single isomer SSRI escitalopram in depressed outpatients. , 2002, The Journal of clinical psychiatry.

[71]  Amitabh Chandra,et al.  Productivity Spillovers in Health Care: Evidence from the Treatment of Heart Attacks , 2007, Journal of Political Economy.

[72]  M. Rynn,et al.  Efficacy of sertraline in the treatment of children and adolescents with major depressive disorder: two randomized controlled trials. , 2003, JAMA.

[73]  K. Krishnan,et al.  An 8-week multicenter, parallel-group, double-blind, placebo-controlled study of sertraline in elderly outpatients with major depression. , 2003, The American journal of psychiatry.

[74]  L. Arnold,et al.  Duloxetine versus escitalopram and placebo: an 8-month, double-blind trial in patients with major depressive disorder* , 2007, Current medical research and opinion.

[75]  E. Katz,et al.  A double-blind placebo-controlled multicentre study of sertraline in the acute and continuation treatment of major depression , 1997, European Psychiatry.